Prevent Cardiac Surgery Associated AKI Trial

Launched by GEORGE WASHINGTON UNIVERSITY · Sep 29, 2024

Keywords

ClinConnect Summary

The Prevent Cardiac Surgery Associated AKI Trial is studying how to prevent a serious kidney problem that can happen after heart surgery. In this trial, 242 patients who are scheduled for a specific type of heart surgery called cardiopulmonary bypass will be randomly selected to receive either a daily dose of two supplements—Coenzyme Q10 (CoQ10) and Glutathione (GSH)—or a placebo (a dummy treatment). The goal is to see if these supplements can help protect the kidneys during and after surgery. Participants will start taking the supplements the day before their surgery and continue for up to a week while they are in the hospital. Researchers will also collect blood and urine samples to monitor kidney function and any side effects from the supplements.

To be eligible for this trial, participants need to be adults aged 18 to 70 who are undergoing this specific type of surgery and have healthy kidney function, indicated by a test called Glomerular Filtration Rate (GFR) of 45 ml/min or higher. Those with certain kidney conditions, allergies to the study drugs, or specific medical histories may not be able to participate. This trial is an important step in finding ways to keep kidneys healthy during heart surgery, and patients can expect to be closely monitored throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult 18-70 years of age
• • Undergoing elective CPB (Cardiopulmonary Bypass) surgery
• • Baseline GFR (Glomerular Filtration Rate) ≥45 ml/min
• Exclusion Criteria:
• • GFR (Glomerular Filtration Rate) \<45 ml/min
• • Solitary kidney
• • Status post-kidney transplant
• • Pregnant women
• • Allergy to CoQ10
• • Allergy to Glutathione
• • Allergy to Cellulose